Castle Biosciences has opened a new 55,000-square-foot laboratory and office facility in Scottsdale, Arizona, to support its growing test volumes and long-term expansion. The facility features advanced infrastructure and employee amenities, reflecting the company's commitment to its Arizona workforce and operations. This expansion is expected to enhance Castle's ability to serve patients and clinicians while supporting future growth in the Phoenix metropolitan area. A grand opening event is scheduled for October 6, 2026, with local officials attending.
Castle Biosciences' new laboratory facility in Scottsdale provides context for health sector activity. For readers following health stocks, here is Pluang's market snapshot as of Sep 22, 2026 18:11 WIB: out of 95 priced US health-sector stocks, 50 rose and 38 fell. Notable movers include Adaptive Biotechnologies Corp at USD 27.01 with a 1-day change of -3.05%, and Citius Pharmaceuticals Inc at USD 0.59 with a 1-day change of +2.91%.
Abivax received positive pre-NDA feedback from the U.S. FDA for its drug Obefazimod, marking a key step in its development. Despite a recent price target cut by Wedbush to $118, analysts maintain a "Moderate Buy" consensus with an average target of $...
HSBC and Wells Fargo have downgraded Netflix stock due to declining subscriber engagement and an 8% drop in viewership time. Despite a recent 2.19% stock gain, Netflix shares have fallen over 40% in the past year amid strong competition and weaker or...
Smiths Group reported solid fiscal 2026 results, meeting EPS and revenue expectations with an EPS of $0.66 and revenue of $1.37 billion. The company improved operating profit, driven by strategic portfolio changes including selling non-core divisions...
Cintas Corporation is set to report its Q3 earnings with an expected EPS of $1.35 and revenue of $2.98 billion, up from $2.72 billion last year. The growth is supported by strong customer retention, increased demand for services like AED Rentals, and...
An analyst from Barclays has lowered Constellation Brands' stock price target to $122, slightly above its current trading price near a 52-week low. The company is refining its beer portfolio strategy with brand-specific plans and supply-chain improve...
